Blog
RSS FeedPosted by Michael Wonder on 16 Dec 2021
Patient reported endpoints underrepresented in product information on new drugs
15 December 2021 - An IQWiG team analysed the extent to which patient reported outcomes, which were recorded as endpoints ...
Posted by Michael Wonder on 14 Dec 2021
Health technology assessment: European Commission welcomes the adoption of new rules to improve access to innovative technologies
13 December 2021 - Today, the Regulation on Health Technology Assessment, a deliverable of the EU Pharmaceutical Strategy, has been adopted. ...
Posted by Michael Wonder on 14 Dec 2021
EU regulation passed: G-BA works on European HTA assessment
14 December 2021 - Today the EU Parliament passed the EU-HTA regulation for a joint health technology assessment, which includes, ...
Posted by Michael Wonder on 09 Dec 2021
Nivolumab for the adjuvant treatment of oesophageal carcinoma: indication of minor added benefit
1 December 2021 - Those affected develop fewer relapses than if they wait and see. ...
Posted by Michael Wonder on 09 Dec 2021
Upadacitinib in atopic dermatitis: additional benefit for adults at high dose
1 December 2021 - Women should expect more serious adverse effects than men. ...
Posted by Michael Wonder on 02 Dec 2021
Call for a central portal for clinical study reports
1 December 2021 - In an open-access publication in the Journal of European CME, two authors from IQWiG argue that ...
Posted by Michael Wonder on 24 Nov 2021
Germany's Government to be eyes backdated drug price cuts
24 November 2021 - Germany's prospective three-party government plans to cut prices retroactively for recently-launched prescription drugs to keep health ...
Posted by Michael Wonder on 11 Nov 2021
European Council green lights new rules on health technology assessment, improving access to medicines and simplifying procedures
9 November 2021 - The Council today gave its final go-ahead for the adoption of a regulation on health technology assessment. ...
Posted by Michael Wonder on 08 Nov 2021
Drugs against rare diseases: Libmeldy gene therapy shows additional benefits - Zolgensma cell therapy, on the other hand, does not
4 November 2021 - The Federal Joint Committee (G-BA) today assessed the additional benefit of two active ingredients against very rare, ...
Posted by Michael Wonder on 05 Oct 2021
Nivolumab and ipilimumab: added benefit in pleural mesothelioma with non-epithelioid tumour histology
1 October 2021 - For the first time, a pure antibody combination has been approved as a first-line therapy for ...
Posted by Michael Wonder on 05 Oct 2021
Adjuvant treatment for NSCLC: osimertinib mesylate may benefit certain people
1 October 2021 - Hint of considerable additional benefit if, after complete tumour resection, adjuvant platinum-based chemotherapy has already been ...
Posted by Michael Wonder on 21 Sep 2021
EU-HTA regulation: methodical preparations for implementation start with IQWiG and G-BA
21 September 2021 - The institute and the G-BA are part of a consortium that is developing the methodological basis ...
Posted by Michael Wonder on 16 Sep 2021
With remdesivir, the Federal Joint Committee assesses the additional benefit of an anti-viral COVID-19 drug for the first time
16 September 2021 - Do patients with COVID-19 have a better chance of surviving and recovering faster if they are treated ...
Posted by Michael Wonder on 16 Sep 2021
Nivolumab in skin cancer: additional benefit upgraded on the basis of an indirect comparison
16 September 2021 - For nivolumab (Opdivo), the pharmaceutical company was able to achieve a significantly better result in a second ...
Posted by Michael Wonder on 15 Sep 2021
Venetoclax in acute myeloid leukaemia: indication of a considerable added benefit
15 September 2021 - Third new area of application/those affected still live a good year on average - and thus ...